Stiripentol in Dravet syndrome: Results of a retrospective U.S. study

Epilepsia

Volumn 54, Issue 9, 2013, Pages 1595-1604

  Wirrell, Elaine C ^a   Laux, Linda ^b   Franz, David N ^c   Sullivan, Joseph ^d   Saneto, Russell P ^e   Morse, Richard P ^f   Devinsky, Orrin ^g   Chugani, Harry ^h   Hernandez, Angel ⁱ   Hamiwka, Lorie ^j   Mikati, Mohamad A ^k   Valencia, Ignacio ^l   Le Guern, Marie Emmanuelle ^m   Chancharme, Laurent ^m   De Menezes, Marcio Sotero ⁿ  

^a MAYO CLINIC   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF CINCINNATI   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^g NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h WAYNE STATE UNIVERSITY   (United States)

ⁱ Neonatology Department   (United States)

^j THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^k DUKE UNIVERSITY MEDICAL CENTER   (United States)

^l DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^m Service de Pharmacologie   (France)

ⁿ SWEDISH MEDICAL CENTER   (United States)

more..

Author keywords

Dravet syndrome; Intractable epilepsy; Pediatric epilepsy; Stiripentol

Indexed keywords

ACETAZOLAMIDE; CLOBAZAM; CLONAZEPAM; CLORAZEPATE; ETHOSUXIMIDE; ETIRACETAM; LORAZEPAM; PHENOBARBITAL; STIRIPENTOL; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE;

APPETITE; ARTICLE; CHILD; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EMERGENCY WARD; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEDATION; SEIZURE; SEVERE MYOCLONIC EPILEPSY IN INFANCY; SIDE EFFECT; UNITED STATES;

DRAVET SYNDROME; INTRACTABLE EPILEPSY; PEDIATRIC EPILEPSY; STIRIPENTOL;

ANTICONVULSANTS; BENZODIAZEPINES; CHILD; CHILD, PRESCHOOL; DIOXOLANES; DRUG THERAPY, COMBINATION; EPILEPSIES, MYOCLONIC; FEMALE; HUMANS; INFANT; MALE; RETROSPECTIVE STUDIES; SEIZURES; TREATMENT OUTCOME; UNITED STATES; VALPROIC ACID;

EID: 84883742045     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/epi.12303     Document Type: Article

References (23)

1. Akiyama M, Kobayashi K, Yoshinaga H, Ohtsuka Y,. (2010) A long-term follow-up study of Dravet syndrome up to adulthood. Epilepsia 51: 1043-1052.
2. Brunklaus A, Ellis R, Reavey E, Forbes GH, Zuberi SM,. (2012) Prognostic, clinical and demographic features in SCN1A mutation-positive Dravet syndrome. Brain 135: 2329-2336.
3. Caraballo RH,. (2011) Nonpharmacologic treatments of Dravet syndrome: focus on the ketogenic diet. Epilepsia 52 (Suppl. 2): 79-82.
4. Ceulemans B, Boel M, Leyssens K, Van Rossem C, Neels P, Jorens PG, Lagae L,. (2012) Successful use of fenfluramine as an add-on treatment for Dravet syndrome. Epilepsia 53: 1131-1139.
5. Chiron C, Dulac O,. (2011) The pharmacologic treatment of Dravet syndrome. Epilepsia 52 (Suppl. 2): 72-75.
6. Chiron C, Marchand MC, Tran A, Rey E, d'Athis P, Vincent J, Dulac O, Pons G,. (2000) Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet 356: 1638-1642.
7. Coppola G, Capovilla G, Montagnini A, Romeo A, Spano M, Tortorella G, Veggiotti P, Viri M, Pascotto A,. (2002) Topiramate as add-on drug in severe myoclonic epilepsy in infancy: an Italian multicenter open trial. Epilepsy Res 49: 45-48.
8. Fisher JL,. (2009) The anti-convulsant stiripentol acts directly on the GABA(A) receptor as a positive allosteric modulator. Neuropharmacology 56: 190-197.
9. Fisher JL,. (2011) Interactions between modulators of the GABA(A) receptor: stiripentol and benzodiazepines. Eur J Pharmacol 654: 160-165.
10. Genton P, Velizarova R, Dravet C,. (2011) Dravet syndrome: the long-term outcome. Epilepsia 52 (Suppl. 2): 44-49.
11. Giraud C, Treluyer JM, Rey E, Chiron C, Vincent J, Pons G, Tran A,. (2006) In vitro and in vivo inhibitory effect of stiripentol on clobazam metabolism. Drug Metab Dispos 34: 608-611.
12. Grosenbaugh DK, Mott DD,. (2013) Stiripentol is anticonvulsant by potentiating GABAergic transmission in a model of benzodiazepine-refractory status epilepticus. Neuropharmacology 67: 136-143.
13. Inoue Y, Ohtsuka Y, Oguni H, Tohyama J, Baba H, Fukushima K, Ohtani H, Takahashi Y, Ikeda S,. (2009) Stiripentol open study in Japanese patients with Dravet syndrome. Epilepsia 50: 2362-2368.
14. Kang HC, Kim YJ, Kim DW, Kim HD,. (2005) Efficacy and safety of the ketogenic diet for intractable childhood epilepsy: Korean multicentric experience. Epilepsia 46: 272-279.
15. Laurie DJ, Wisden W, Seeburg PH,. (1992) The distribution of thirteen GABAA receptor subunit mRNAs in the rat brain. III. Embryonic and postnatal development. J Neurosci 12: 4151-4172.
16. Nabbout R, Copioli C, Chipaux M, Chemaly N, Desguerre I, Dulac O, Chiron C,. (2011) Ketogenic diet also benefits Dravet syndrome patients receiving stiripentol: a prospective pilot study. Epilepsia 52: e54-e57.
17. Quilichini PP, Chiron C, Ben-Ari Y, Gozlan H,. (2006) Stiripentol, a putative antiepileptic drug, enhances the duration of opening of GABA-A receptor channels. Epilepsia 47: 704-716.
18. Ragona E,. (2011) Cognitive development in children with Dravet syndrome. Epilepsia 52 (Suppl. 2): 39-43.
19. Sakauchi M, Oguni H, Kato I, Osawa M, Hirose S, Kaneko S, Takahashi Y, Takayama R, Fujiwara T,. (2011) Retrospective multiinstitutional study of the prevalence of early death in Dravet syndrome. Epilepsia 52: 1144-1149.
20. Skluzacek JV, Watts KP, Parsy O, Wical B, Camfield P,. (2011) Dravet syndrome and parent associations: the IDEA League experience with comorbid conditions, mortality, management, adaptation, and grief. Epilepsia 52 (Suppl. 2): 95-101.
21. Tanabe T, Awaya Y, Matsuishi T, Iyoda K, Nagai T, Kurihara M, Yamamoto K, Minagawa K, Maekawa K,. (2008) Management of and prophylaxis against status epilepticus in children with severe myoclonic epilepsy in infancy (SMEI; Dravet syndrome)-a nationwide questionnaire survey in Japan. Brain Dev 30: 629-635.
22. Thanh TN, Chiron C, Dellatolas G, Rey E, Pons G, Vincent J, Dulac O,. (2002) Long-term efficacy and tolerance of stiripentaol in severe myoclonic epilepsy of infancy (Dravet's syndrome). Arch Pediatr 9: 1120-1127.
23. Tran A, Rey E, Pons G, Rousseau M, d'Athis P, Olive G, Mather GG, Bishop FE, Wurden CJ, Labroo R, Trager WF, Kunze KL, Thummel KE, Vincent JC, Gillardin JM, Lepage F, Levy RH,. (1997) Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: in vitro and in vivo comparison and calculation of in vivo inhibition constants. Clin Pharmacol Ther 62: 490-504.